GO
Loading...

Scor Makes Hostile Bid for Converium

Scor, the French reinsurance company, launched a hostile bid for the remaining shares in Converium Monday, Scor’s Zurich-based rival, but investors held out for more than the $2 billion offer, Reuters reported. The proposed merger would create one of the world's top five reinsurers.

Converium rejected Scor's informal offer of 21 Swiss francs a share last week, which valued the whole company at about 3 billion francs ($2.4 billion). The rejection led takeover talks to break down, according to Reuters.

Scor claimed it had the support of Converium's main shareholders and would go ahead and present investors with a hostile bid over the heads of management, Reuters reported.

Scor plans to offer half a new Scor share plus 4 Swiss francs in cash for each Converium share, starting in April. Excluding the shares it has already bought, the new offer would cost Scor 2.4 billion Swiss francs, or $1.9 billion, according to Reuters.

Converium again rejected the Scor revised announcement, saying it changed nothing from the French company's previous approach, said Reuters.

Featured

  • The Marriner S. Eccles Federal Reserve building in Washington.

    CNBC's Fed Survey shows market pros aren't very confident the Fed can end its easy money polices without a market crash, a recession or bad inflation.

  • Merck employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck reported better-than-expected results, with sales of newer drugs offsetting declining sales of drugs facing generic competition.

  • Pfizer reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • An attendee is silhouetted against a Microsoft poster at the Microsoft Developers Build Conference in San Francisco, April 2, 2014.

    An agency that enforces antimonopoly laws visited company offices in four cities, as the country more closely scrutinizes multinational companies.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video